A Phase 2 interventional study of 400 µg Brimonidine Implant and Sham in Geographic Atrophy and Macular Degeneration, sponsored by Allergan. Terminated at 41 sites in 6 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2019-04-23.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 22nd largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2014, is one of 43 in phase 2, and was the 32nd registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 2 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
Drug: 400 µg Brimonidine Implant
Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
Other: Sham
400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
Also known as: AGN-190342
Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
Change From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 24
GA lesion area was measured in mm\^2 by FAF in the study eye and was quantified by the central reading center. The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard Best Correct Visual Acuity (BCVA). If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression). Mixed model for repeated measures (MMRM) was used for analysis.
Time frame: Baseline (Day 1) to Month 24
Change From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24
BCVA was measured using an eye chart (ETDRS) and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.
Time frame: Baseline (Day 1) to Month 24
Change From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24
Low Luminance BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.
Time frame: Baseline (Day 1) to Month 24
Change From Baseline in Retinal Sensitivity in the Study Eye
Time frame: Baseline (Day 1) to Month 24
| Milestone | 400 µg Brimonidine Implant | Sham |
|---|---|---|
| Started | 154 | 156 |
| Completed | 34 | 40 |
| Not completed | 120 | 116 |
| Withdrew: Adverse event | 10 | 14 |
| Withdrew: Lack of efficacy | 4 | 3 |
| Withdrew: Lost to follow-up | 6 | 4 |
| Withdrew: Withdrawal by subject | 9 | 11 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Study terminated by sponsor | 87 | 80 |
| Withdrew: Other miscellaneous reasons | 3 | 4 |
GA lesion area was measured in mm\^2 by FAF in the study eye and was quantified by the central reading center. The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard Best Correct Visual Acuity (BCVA). If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression). Mixed model for repeated measures (MMRM) was used for analysis.
| mm^2 | 400 µg Brimonidine Implant | Sham |
|---|---|---|
| Change From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 24 | 3.1455 ± 0.1377 | 3.5044 ± 0.1359 |
BCVA was measured using an eye chart (ETDRS) and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.
| letters read correctly | 400 µg Brimonidine Implant | Sham |
|---|---|---|
| Change From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24 | -10.9 ± 1.0 | -9.7 ± 1.0 |
Low Luminance BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.
| letters read correctly | 400 µg Brimonidine Implant | Sham |
|---|---|---|
| Change From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24 | -8.1 ± 1.0 | -6.7 ± 1.0 |
Results for this outcome have not been posted.
Collected over From first dose of study drug to date of last visit (up to approximately 33 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 µg Brimonidine Implant | 5/154 (3.2%) | 48/154 (31.2%) | 79/154 (51.3%) |
| Sham | 6/156 (3.8%) | 37/156 (23.7%) | 61/156 (39.1%) |
| Event | 400 µg Brimonidine Implant | Sham |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 3/154 | 0/156 |
| Atrial fibrillationCardiac disorders | 3/154 | 1/156 |
| BradycardiaCardiac disorders | 3/154 | 0/156 |
| Cardiac failure congestiveCardiac disorders | 3/154 | 1/156 |
| PneumoniaInfections and infestations | 3/154 | 3/156 |
| Coronary artery diseaseCardiac disorders | 2/154 | 1/156 |
| Sinus node dysfunctionCardiac disorders | 2/154 | 0/156 |
| Visual acuity reducedEye disorders | 2/154 | 0/156 |
| Vitreous haemorrhageEye disorders | 2/154 | 0/156 |
| FallInjury, poisoning and procedural complications | 2/154 | 2/156 |
| Event | 400 µg Brimonidine Implant | Sham |
|---|---|---|
| Vitreous floatersEye disorders | 29/154 | 1/156 |
| Conjunctival haemorrhageEye disorders | 21/154 | 11/156 |
| Urinary tract infectionInfections and infestations | 3/154 | 15/156 |
| Visual impairmentEye disorders | 12/154 | 6/156 |
| NasopharyngitisInfections and infestations | 12/154 | 12/156 |
| Eye painEye disorders | 11/154 | 9/156 |
| HypertensionVascular disorders | 8/154 | 11/156 |
| FallInjury, poisoning and procedural complications | 5/154 | 10/156 |
| Visual acuity reducedEye disorders | 9/154 | 6/156 |
| Dry eyeEye disorders | 8/154 | 6/156 |
All randomized participants.
| Age, Continuous(years) | 400 µg Brimonidine Implant | Sham | Total |
|---|---|---|---|
| Mean | 76.9 ± 7.89 | 77.0 ± 7.24 | 76.9 ± 7.56 |
| Sex: Female, Male(Participants) | 400 µg Brimonidine Implant | Sham | Total |
|---|---|---|---|
| Female | 101 | 91 | 192 |
| Male | 53 | 65 | 118 |
| Race/Ethnicity, Customized(Participants) | 400 µg Brimonidine Implant | Sham | Total |
|---|---|---|---|
| White | 153 | 156 | 309 |
| Black or African American | 1 | 0 | 1 |
| Geographic Atrophy (GA) Lesion Area by Fundus Autofluorescence (FAF)(millimeters squared (mm^2)) | 400 µg Brimonidine Implant | Sham | Total |
|---|---|---|---|
| Mean | 5.1611 ± 3.7016 | 5.4761 ± 3.5961 | 5.3212 ± 3.6457 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2014 to primary completion in Mar 2018, 46 months.
Results were first posted in Apr 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine